Elsevier

Current Opinion in Immunology

Volume 43, December 2016, Pages 74-80
Current Opinion in Immunology

T cell exhaustion and immune-mediated disease  the potential for therapeutic exhaustion

https://doi.org/10.1016/j.coi.2016.09.005Get rights and content

Highlights

  • T cell exhaustion represents a continuous spectrum of CD8 T cell dysfunction defined in models of chronic viral infection.

  • It is associated with persistent viraemia and is a target of immune checkpoint therapy in cancer.

  • By contrast it is associated with favourable long-term outcome in chronic inflammatory diseases.

  • Modulation of inhibitory receptor signalling can reverse exhaustion in chronic infection and cancer and may prove a useful strategy to modulate the long-term course of immune-mediated disease.

  • Understanding the biology underlying immune responses to chronic infection may inform the biology determining clinical outcome in autoimmunity.

T cell exhaustion represents a continuous spectrum of cellular dysfunction induced during chronic viral infection, facilitating viral persistence and associating with poor clinical outcome. Modulation of T cell exhaustion can restore function in exhausted CD8 T cells, promoting viral clearance. Exhaustion has also been implicated as playing an important role in anti-tumour responses, whereby exhausted tumour-infiltrating lymphocytes fail to control tumour progression. More recently exhaustion has been linked to long-term clinical outcome in multiple autoimmune diseases but, in contrast to cancer or infection, it is associated with a favourable clinical outcome characterised by fewer relapses. An increasing understanding of key inhibitory signals promoting exhaustion has led to advances in therapy for chronic infection and cancer. An increasing understanding of this biology may facilitate novel treatment approaches for autoimmunity through the therapeutic induction of exhaustion.

Introduction

The clinical course of immune-mediated disease is highly variable  two individuals presenting with the same diagnosis may subsequently follow markedly different clinical courses, ranging from frequent relapses, disease progression and death to long-term stable remission with minimal treatment. While many studies have focussed on the factors predisposing to the onset of autoreactivity [1], there has been little consideration of the factors controlling disease course once autoimmunity is established. It is now becoming clear that the biology underlying a relapsing or quiescent disease course may be largely distinct from that which predisposes to broken self tolerance in the first place [2, 3••]. This biology has been historically neglected, in part because it requires the more demanding, prospective collection of long-term follow-up data. Its relevance to treatment strategies is, however, arguably more pertinent  it may prove more tractable to modulate pathways controlling a chronic autoimmune response than to strive to restore tolerance itself.

While these strategies are partially overlapping, recent observations that analogous responses to chronic antigen occur during chronic viral infection, autoinflammatory diseases and the anti-tumour response have suggested the potential for a new framework for modifying chronic inflammatory disease through modulation of a process known as T cell exhaustion.

Section snippets

Definition and evolution of exhaustion

Following transient exposure to antigen, such as during acute viral infection, antigen-specific T cells undergo rapid proliferation followed by a more prolonged contraction phase. Following this, the population of memory cells that remain confer protective immunity, characterised by higher proliferative potential, a reduced activation threshold and the ability to persist long-term in the absence of cognate antigen [4]. However, where antigen persists, such as during chronic viral infection, CD8

Manipulating exhaustion: checkpoint blockade and agonists

While CD8 exhaustion is known to limit viral control during chronic infection, exhausted cells may also be restored to useful function by blocking inhibitory signalling through PD-1, resulting in reduced viral loads even in the absence of a CD4-helper response [12••]. In addition, immune checkpoint therapy targeting exhaustion-associated T cell inhibitory receptors restores effective anti-tumour T cell responses, producing a durable clinical response in a subset of patients [19]. Such

Exhaustion, anergy and senescence

While exhausted CD8 cells retain the capacity to differentiate in to robust memory cells [12••], other states of T cell dysfunction such as anergy and senescence do not show similar plasticity. Exhausted CD8 T cells can be reinvigorated by transfer from chronically LCMV-cl13 infected to uninfected mice (although this potential is ultimately lost later in the course of persistent infection) [24]. This observation highlights the role of complex CD8-extrinsic inhibitory signals from multiple

Reversing exhaustion, inducing immune-mediated disease

Exhaustion has likely evolved to protect the host from collateral immunopathology that would accompany a robust attempt to eradicate a chronic virus. Exhaustion may therefore work in the hosts favour, at least during non-cytopathic viral infection (e.g. LCMV, HBV, HCV) where the immediate consequences of ‘tolerating’ the virus are not problematic. Clearly, avoiding early immunopathology does come at a cost, however, as permitting chronic infection brings different long-term problems (such as

Inducing exhaustion, controlling immune-mediated disease?

As a state of CD8 exhaustion shows plasticity and may be reversed, we have proposed that it may be possible to induce T cell exhaustion as a novel therapeutic approach for autoimmune disease. This concept is supported by observations that a transcriptional signature of exhaustion associates with protection from a relapsing course in multiple autoimmune diseases [3••], that LCMV-cl13 infection can prevent the onset of virally induced autoimmunity in a mouse expressing a viral transgene as an

The challenge of inducing exhaustion

Therapeutic induction of T cell exhaustion in autoimmunity is a logical proposition. However, there are several important caveats to consider. Firstly, reversal of CD8 T cell exhaustion is facilitated by persistent high-level expression of the inhibitory receptors promoting it  in other words, there is a clear surface receptor target to block. In order to promote exhaustion, a checkpoint agonist must target robustly costimulated memory-like CD8 cells that, by definition, express only minimal

Conclusions

CD8 T cell exhaustion has been associated with clinical outcome in immune-mediated disease. It is plausible that in chronic inflammatory disease, as in chronic infection and cancer, exhaustion is not just associated with outcome, but dictates it. Consequently, therapeutic induction of T cell exhaustion represents a novel strategy to achieve improved long-term control of immune-mediated disease and remains of focus of ongoing research.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

  • • of special interest

  • •• of outstanding interest

Acknowledgements

This work was supported by The National Institute of Health Research (NIHR), Cambridge Biomedical Research Centre, the Wellcome Trust (project 094227/Z/10/Z and program grants 083650/Z/07/Z), a Lister Prize Fellowship (KGCS) and the Lupus Research Institute (Distinguished Innovator Award, KGCS). EFM is a Wellcome–Beit Research Fellow supported by the Wellcome Trust and Beit Foundation (104064/Z/14/Z).

References (55)

  • S.M. Kaech et al.

    Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells

    Nat Immunol

    (2001)
  • E.F. McKinney et al.

    T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection

    Nature

    (2015)
  • E.J. Wherry et al.

    Memory CD8 T-cell differentiation during viral infection

    J Virol

    (2004)
  • A.J. Zajac et al.

    Viral immune evasion due to persistence of activated T cells without effector function

    J Exp Med

    (1998)
  • R. Ahmed et al.

    Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence

    J Exp Med

    (1984)
  • E.J. Wherry

    T cell exhaustion

    Nat Immunol

    (2011)
  • B.M. Sullivan et al.

    Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence

    Proc Natl Acad Sci U S A

    (2011)
  • E.B. Wilson et al.

    Emergence of distinct multiarmed immunoregulatory antigen-presenting cells during persistent viral infection

    Cell Host Microbe

    (2012)
  • E.J. Wherry et al.

    Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment

    J Virol

    (2003)
  • D.L. Barber et al.

    Restoring function in exhausted CD8 T cells during chronic viral infection

    Nature

    (2006)
  • P. Waterhouse et al.

    Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

    Science

    (1995)
  • L. Monney et al.

    Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

    Nature

    (2002)
  • J. Naidoo et al.

    Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

    Ann Oncol

    (2016)
  • M. Cornberg et al.

    Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response

    Front Immunol

    (2013)
  • R.H. Schwartz

    T cell anergy

    Annu Rev Immunol

    (2003)
  • K.E. Pauken et al.

    Overcoming T cell exhaustion in infection and cancer

    Trends Immunol

    (2015)
  • J.E. Schmitz et al.

    Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

    Science

    (1999)
  • Cited by (63)

    • Nucleic acid biomarker technology for cancer immunotherapy

      2022, Engineering Technologies and Clinical Translation: Volume 3 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
    • Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy

      2021, Translational Research
      Citation Excerpt :

      T-cell exhaustion, of which T-cell hyporesponsiveness44 is an important feature, has been receiving increasing attention in a myriad of diseases. This is the result of chronic T-cell stimulation, and has been described in chronic viral infections, classically lymphocytic choriomeningitis virus infections in mice,45 as well as in cancer.44 Recently, T-cell exhaustion has also been described in a range of chronic autoimmune diseases, ranging from ANCA-associated vasculitis, lupus, and inflammatory bowel disease.46

    View all citing articles on Scopus
    View full text